<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03554200</url>
  </required_header>
  <id_info>
    <org_study_id>15-156</org_study_id>
    <secondary_id>2017-002695-45</secondary_id>
    <nct_id>NCT03554200</nct_id>
  </id_info>
  <brief_title>EMPA Acute Heart Failure</brief_title>
  <official_title>Effect of Empagliflozin on Cardiac Output in Patients With Acute Heart Failure (EMPA Acute Heart Failure)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators are aiming to treat patients with acute heart failure with or
      without diabetes with Empagliflozin or placebo. Given the beneficial effects of Empagliflozin
      on heart failure hospitalization in the EMPA-REG OUTCOME trial, the investigators do expect a
      similar beneficial effect to be present in patients with acute heart failure. Acute heart
      failure is a state of hydropic decompensation resulting in dyspnea and congestions, caused by
      different etiologies of cardiac disease. Recompensation is reached by application of diuretic
      drugs and fluid restriction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the present study patients will be randomized into 2 groups (standard of care +
      Empagliflozin 10 mg/d or standard of care + placebo). Cardiac output will be assessed by a
      medical device for noninvasive monitoring of hemodynamic parameters (cardiac output, systemic
      vascular resistance, stroke volume and blood pressure) using finger cuff technology for pulse
      contour analysis.

      These investigations will inform about Empagliflozin dependent effects on hemodynamic and
      cardiac function in patients with acute heart failure. The investigation will further assess
      the therapeutic efficacy of Empagliflozin on heart failure symptoms using objective
      (respiratory rate, oxygen requirement, peak expiratory flow rate, urinary volume, body
      weight, diuretic requirement, length of hospital stay) and well accepted, patient orientated
      secondary endpoints. In addition, metabolic regulators and parameters relevant for cardiac
      function and substrate metabolism will be assessed to further investigate possible mechanisms
      of Empagliflozin-dependent actions on cardiac function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single center, prospective, placebo-controlled, double blind, randomized, 2-arm parallel, interventional, exploratory pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This trial is double-blinded. After randomization neither the patients nor the investigator will be aware of the treatment allocation. Patients assigned to one of the double-blinded treatment will take one tablet Empagliflozin or matching placebo. The tablets will be identical in appearance.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>effect of Empagliflozin 10mg qd versus placebo on cardiac output in patients with acute heart failure</measure>
    <time_frame>30 days</time_frame>
    <description>by ClearSight System</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics</measure>
    <time_frame>30 days</time_frame>
    <description>Stroke volume (ml/beat)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardio vascular</measure>
    <time_frame>30 days</time_frame>
    <description>blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Empagliflozin on systemic quality of life</measure>
    <time_frame>30 days</time_frame>
    <description>Quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Empagliflozin on hospitalization due to cardiovascular causes or readmission for heart failure or renal failure</measure>
    <time_frame>30 days</time_frame>
    <description>length of initial hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Empagliflozin on death due to cardiovascular causes</measure>
    <time_frame>30 days</time_frame>
    <description>days alive and out of hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine</measure>
    <time_frame>30 days</time_frame>
    <description>24 h sodium excretion (mmol/day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>30 days</time_frame>
    <description>body weight (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardio vascular</measure>
    <time_frame>30 days</time_frame>
    <description>24 h heart rate (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood</measure>
    <time_frame>30 days</time_frame>
    <description>NT-proBNP (ng/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood</measure>
    <time_frame>30 days</time_frame>
    <description>cystatin C(mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood</measure>
    <time_frame>30 days</time_frame>
    <description>serum levels of Glucose (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>30 days</time_frame>
    <description>breaths/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diuretic response</measure>
    <time_frame>30 days</time_frame>
    <description>Δ weight kg/[(total i.v. dose)/40mg]+[(total oral dose)/80mg)] furosemide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney injury risk score</measure>
    <time_frame>30 days</time_frame>
    <description>by NephroCheck® (defined by TIMP-2 x IGFBP7 in urine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of microbiome</measure>
    <time_frame>30 days</time_frame>
    <description>stool sample</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive empagliflozin 10 mg qd for a period of 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients of the placebo arm will receive placebo tablets qd for a period of 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Standard of Care + Empagliflozin: 10 mg (tablets) once daily</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Standard of Care + Placebo: Matching Placebo (tablets) once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Patients with acute heart failure with associated signs or symptoms (dyspnea on
             exertion, orthopnea, paroxysmal dyspnea, peripheral oedema, chest x-ray with pulmonary
             congestion)

          3. Serum levels of NT-proBNP ≥ 1000 pg/ml

          4. Written informed consent prior to study participation

        Exclusion Criteria:

          1. Type 1 diabetes

          2. Participants of child-bearing age without adequate contraception

          3. Pregnancy or lactating females

          4. Cardiogenic shock

          5. Acute coronary syndrome within 30 days prior to randomization

          6. Planned or recent percutaneous or surgical coronary intervention within 30 days prior
             to randomization

          7. Signs of ketoacidosis and/or hyperosmolar hyperglycemic syndrome (pH ≤ 7.30 and
             glucose &gt;14 mmol/l and HCO3- ≤ 18 mmol/l)

          8. Signs of active infection

          9. Dyspnea due to non-cardiac causes (severe pulmonary disease, anemia, severe obesity)

         10. Coronary artery disease with requirement for revascularization within the study period

         11. Renal impairment (GFR &lt; 30 ml/min/1,73 m2)

         12. Liver disease (serum levels of AST, ALT or AP more than three times the upper limit of
             normal)

         13. Uncontrolled thyroid disease

         14. Endocrinopathies like Graves' disease, acromegaly, Cushings' disease

         15. Hypertensive retinopathy or encephalopathy

         16. Bariatric surgery in last 2 years prior to randomization

         17. Patients in whom study participation is not deemed appropriate under consideration of
             clinical wellbeing by the principal investigator

         18. The subject is mentally or legally incapacitated

         19. The subject received an investigational drug within 30 days prior to inclusion into
             this study

         20. Urinary tract infections or significant formation of residual urine in medical history

         21. Patients with particular risk for ketoacidosis (alcohol abuse, pancreatitis,
             pancreatic insulin deficiency from any cause, caloric restriction etc.) or
             ketoacidosis in the past

         22. Frequent hypoglycaemic events (in the opinion of the investigator)

         23. Intolerance to Empagliflozin and excipients in Empagliflozin or rather placebo
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Lehrke, Dr</last_name>
    <phone>+49 241 8089301</phone>
    <email>mlehrke@ukaachen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Internal Medicine I RWTH Aachen University Hospital</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lehrke, PD Dr. med.</last_name>
      <phone>+49 241 80 85152</phone>
      <email>mlehrke@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Michael Lehrke, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikolaus Marx, Univ.-Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Empagliflozin</keyword>
  <keyword>acute heart failure</keyword>
  <keyword>cardiac output</keyword>
  <keyword>left ventricular systolic and diastolic function</keyword>
  <keyword>exercise capacity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

